checkAd

    SCYNEXIS to Participate in Antifungals Panel at Maxim Group’s Infectious Disease Virtual Conference  137  0 Kommentare The Renaissance of the Anti-infective Sector

    JERSEY CITY, N.J., April 28, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will participate in a panel discussion on fungal pathogens and the emerging treatment landscape at Maxim Group’s Infectious Disease Virtual Conference on May 5, 2020.

    Panel Details:
    Topic: Antifungals
    Time: 12:15 p.m. EDT to 1:45 p.m. EDT
    To register for the virtual conference, please click here: Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector.

    “The current pandemic has highlighted how devastating infectious diseases can be and reinforced the importance of proactively developing novel anti-infectives capable of combating emerging threats in our never-ending warfare against evolving pathogens,” said Dr. Taglietti. “There has been little innovation in the antifungal treatment landscape over the last 20 years and we hope to contribute to the field by advancing a new class of antifungals with the potential to treat a broad range of fungal infections, from common vaginal yeast infections, where there is only one oral treatment available for women, to life-threatening infections such as Candida auris, an emerging fungal pathogen designated by the CDC as an urgent global health threat.”

    SCYNEXIS is focused on advancing its lead candidate, ibrexafungerp, a broad-spectrum, oral and intravenous antifungal agent representing a novel therapeutic class with the potential to combat pathogens resistant to current treatment options. SCYNEXIS recently released positive top-line results from its second pivotal Phase 3 study (VANISH-306) of oral ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC), commonly known as vaginal yeast infection and plans to submit a New Drug Application for this indication in the second half of 2020. SCYNEXIS also recently released the second set of positive interim results from its ongoing Phase 3 study (FURI) evaluating oral ibrexafungerp as a salvage treatment in patients with difficult-to-treat mucocutaneous and invasive fungal infections that are refractory to or intolerant of current standards of care, or require a non-azole oral step-down therapy for treatment of azole-resistant Candida species.

    Seite 1 von 3


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    SCYNEXIS to Participate in Antifungals Panel at Maxim Group’s Infectious Disease Virtual Conference The Renaissance of the Anti-infective Sector JERSEY CITY, N.J., April 28, 2020 (GLOBE NEWSWIRE) - SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco …